Aligning research and innovation through the European Partnership on One Health and Antimicrobial Resistance (EUP OHAMR)
- Countries
- 30 countries across Europe
- Status
- Ongoing
- Duration
- June 2025-Jun 2035
- Funder
- European Commission
Antimicrobial resistance (AMR) is a global health challenge that affects human and animal health, food security and the environment. The European Partnership on One Health and Antimicrobial Resistance (EUP OHAMR) brings together 53 organisations from 30 countries across the EU and beyond, aiming to close knowledge gaps and break silos between sectors, disciplines and perspectives. KIT Institute contributes to work packages aiming to: strengthen One Health and AMR research capacity; improve the reuse and interoperability of AMR data; support exchange, transfer and uptake of AMR research into policy and practice.
In 2019, global AMR-related deaths were higher than those from HIV/AIDS and malaria. The global AMR burden could rise by up to as much as 70% by 2050 without action. Coherent funding for AMR research and innovation can help us better understand the biological mechanisms of resistance and evolution in microorganisms, as well as the sociological factors that influence how AMR spreads among humans.
The formation of the European Partnership on One Health and Antimicrobial Resistance (EUP OHAMR) was proposed by the European Commission to align R&I funding among EU countries and beyond. The partnership builds on the legacy of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), which invested over €180 million for research projects and networks between 2011 and 2024.
KIT Institute is one of the 53 partners and contributes to Work Packages 4, 5 and 6 which focus on, respectively: strengthening capacity for sustainable AMR research (WP4); maximising the use and reuse of AMR-related resources for research and innovation (WP5); knowledge valorisation to support exchange, transfer and uptake of research and innovation outcomes by end-users (WP6).
The Partnership will pool approximately €250 million across its ten-year lifecycle for research and innovation projects, guided by its Strategic Research and Innovation Agenda. The first Joint Transnational Call on ‘Treatments and adherence to treatment protocols’ was launched on the 18th of November 2025 with a total budget of €31 million. Every year, there will be successive calls to fund both the AMR research and the support of capacity strengthening and knowledge exchange.
